Gentium price target raised to $60 from $38 at Brean Capital Brean Capital raised Gentium's price target to $60 following the EMA approval of Defibrotide.
http://www.theflyonthewall.com/permalinks/entry.php/GENTid1910585/GENT-Gentium-reports-Q-EPS-EUR-c-consensus-c
http://www.theflyonthewall.com/permalinks/entry.php/GENTid1910585/GENT-Gentium-reports-Q-EPS-EUR-c-consensus-c
No comments:
Post a Comment